Edition:
United Kingdom

Rosetta Genomics Ltd (ROSG.OQ)

ROSG.OQ on NASDAQ Stock Exchange Capital Market

0.65USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
46,345
52-wk High
$7.08
52-wk Low
$0.60

Latest Key Developments (Source: Significant Developments)

Rosetta Genomics suspends 2017 revenue and unit guidance for Reveal‍​
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Rosetta Genomics Ltd ::Says suspends its previously announced 2017 revenue and unit guidance for Reveal - SEC filing ‍​.Says intends to update its Reveal revenue and unit guidance by year-end 2017.  Full Article

Rosetta Genomics fortifies intellectual property portfolio with two new patent allowances
Monday, 3 Oct 2016 

Rosetta Genomics Ltd : Rosetta genomics fortifies intellectual property portfolio with two new patent allowances for its novel microrna platform technology . Allowed korean patent claims method for diagnosing various cancers, using expression profile of hsa-mir-192, hsa-mir-200c, hsa-mir-193a .Received a notice of allowance from kipo for korean patent application no. 2010-7007495.  Full Article

Rosetta Genomics enters distribution agreement for RosettaGX Reveal in Israel with Rhenium
Thursday, 29 Sep 2016 

Rosetta Genomics Ltd : Rosetta genomics enters distribution agreement for rosettagx reveal(tm) in israel with rhenium . Rosetta genomics enters distribution agreement for rosettagx reveal(tm) in israel with rhenium . Rosetta genomics ltd says thyroid cancer diagnostic assay will be covered by israel's largest health insurance company .Under terms of agreement, rhenium's exclusivity is contingent on rhenium meeting certain volume commitments.  Full Article

Rosetta Genomics Q2 non-gaap loss per share $0.15 excluding items
Monday, 26 Sep 2016 

Rosetta Genomics Ltd : Rosetta genomics reports 2016 second quarter financial results . Q2 loss per share $0.16 . Q2 revenue rose 23 percent to $2.4 million . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Q2 non-gaap loss per share $0.15 excluding items ."in q3 we expect approximately 300 reveal orders with gross billings of approximately $900,000".  Full Article

Rosetta Genomics gets notice of rescission of conditional approval from New York State Department of Health for 4 of co's Allele-specific PCR-based assays
Monday, 22 Aug 2016 

Rosetta Genomics Ltd : Got notice of rescission of conditional approval from new york state department of health for 4 of co's Allele-specific PCR-based assays . "Confident" it will be able to address concerns raised by Nysdoh, plans to resubmit for nysdoh approval as soon as possible-sec filing .In the interim, the company will not process samples for co’s Allele-specific PCR-based assays from patients in New York.  Full Article

Rosetta Genomics inks new agreement with Galaxy Health Network
Tuesday, 2 Aug 2016 

Rosetta Genomics Ltd :Rosetta expands managed care coverage with new preferred provider agreement with Galaxy Health Network for entire suite of diagnostic tests and services.  Full Article

Rosetta Genomics Ltd announces agreement with Preferred Provider Organization
Thursday, 23 Jun 2016 

Rosetta Genomics Ltd :Rosetta expands managed care coverage with new preferred provider agreement for entire suite of diagnostic tests and services.  Full Article

Rosetta Genomics announces receipt of conditional approval
Monday, 23 May 2016 

Rosetta Genomics Ltd :Receipt of conditional approval from new york state department of health for company's allele-specific pcr based assays.  Full Article

Rosetta Genomics Q1 non-gaap loss per share $0.18 excluding items
Thursday, 19 May 2016 

Rosetta Genomics Ltd : Company's current operations and plans include a cost-reduction plan should it be unable to raise sufficient additional capital . Expects its current cash position will fund operations for at least next 12 months . Rosetta genomics reports 2016 first quarter financial results . Q1 loss per share $0.20 . Q1 non-gaap loss per share $0.18 excluding items .Q1 revenue rose 711 percent to $2.6 million.  Full Article

BRIEF-Rosetta Genomics suspends 2017 revenue and unit guidance for Reveal‍​

* Says suspends its previously announced 2017 revenue and unit guidance for Reveal - SEC filing ‍​